DETROIT, Aug. 16, 2023 /PRNewswire/ — Functional Fluidics, a US-based biotechnology company, proudly announces its global expansion into Africa in the fourth quarter of 2023.
For nearly a decade, Functional Fluidics has been offering a suite of clinically validated assays to pharmaceutical companies and clinical providers across the United States to help support sickle cell disease new drug development and overall patient care.
Sickle cell disease is a globally prevalent genetic disorder. It is estimated that around 300,000 babies are born with sickle cell disease (SCD) each year worldwide. Sub-Saharan African countries bear a significant burden with a high prevalence of SCD and play an important role in the global landscape of sickle cell disease.
“Functional Fluidics is taking a proactive approach by establishing new operations in sub-Saharan Africa starting in Nigeria in 2023. We are committed to expanding the access to valuable insights on the health of red blood cells that can be obtained from our portfolio of red blood cell biomarkers. Our goal at Functional Fluidics is to help Life Science innovators accelerate the speed, cost and success rate of bringing new life changing therapies to individuals with Sickle Cell Disease,” said Dr. Patrick Hines, Founder and CEO of Functional Fluidics.
Functional Fluidics’ expansion into Nigeria follows several years of rapid growth and momentum for the company as it strives to be the gold standard for red blood cell health, starting with sickle cell disease.
About Functional Fluidics:
Functional Fluidics is a biotechnology company that specializes in offering valuable insights into the health of red blood cells, addressing the growing demand for reliable biomarkers that objectively monitor the well-being of these cells. With an initial focus on sickle cell disease, the company strives to become the leading authority in red blood cell health. Functional Fluidics integrates clinical trial support, deep scientific knowledge, laboratory expertise and data sciences with the goal of helping our pharmaceutical, biotech and academic partners bring life changing therapies to patients faster, and more cost effectively.
Andre Moxie, Chief Commercial Officer
Functional Fluidics, Inc.
(313) 315-2555, Email: [email protected]
SOURCE Functional Fluidics